CLAIMS

What is claimed is:

1. A compound having the structure of Formula I:



I

or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is CH_3, or CH_2 CH_3,

R^2 is H or CH_3,

R^3 is H or NH_2 and

n is 1 or 2.

2. The compound of Claim 1 wherein n is 1 and R^1 is methyl.

3. The compound of Claim 1 wherein R^2 is methyl.

4. The compound of Claim 1 wherein R^3 is NH_2.

5. The compound of Claim 1 wherein n is 1, R^1 is methyl, R^2 is methyl and R^3 is NH_2.

6. A compound of the Formula (Ii)



(Ii)

7. A compound of the Formula (Iii)



(Iii)

8. A compound of the Formula (Iiii)



(Iiii)

9. A compound of the Formula (Iiv)



(Iiv)

10. A compound of the Formula (Iv)



(Iv)

11. A compound of the Formula (Ivi)



(Ivi)

12. A compound having the structure of Formula II



(II)

or a pharmaceutically acceptable salt thereof,

wherein:

R^1 is CH_3, or CH_2 CH_3,

R^2 is H or CH_3,

R^4 is CH_3, $(CH_2)_4NH_2$, or $(CH_2)_3NHC(=O)NH_2$

R^5 is H; $CH(CH_3)(CH_3)$

R^6 is NHC(=O), or CH_2;

n is 1 or 2; and

m is 0, 1, 2 or 3.

13. The compound of Claim 12 wherein n is 1 and R^1 is methyl.

14. The compound of Claim 12 wherein R^2 is methyl.

15. The compound of Claim 12 wherein n is 1, R^1 is methyl, and R^2 is methyl.

16. The compound of Claim 12 wherein R^4 is $(CH_2)_4NH_2$.

17. The compound of Claim 12 wherein R^5 is H.

18. The compound of Claim 12 wherein R^6 is CH_2.

19. The compound of Claim 12 wherein m is 1.

20. The compound of Claim 12 wherein n is 1, m is 1, R^1 is methyl, R^2 is methyl, R^4 is $(CH_2)_4NH_2$, R^5 is H, and R^6 is CH_2.

21. A compound of the Formula (IIi)



(IIi).

22. A compound of the Formula (IIii)



(IIii)

.

23. A compound of the Formula (IIiii)



(IIiii).

24. A compound of the Formula (IIiv)



(IIiv)

25. A antibody-drug conjugate which is a conjugate of a compound having the structure of Formula II



(II)

wherein:

R^1 is CH_3, or CH_2 CH_3,

R^2 is H or CH_3,

R^4 is CH_3, $(CH_2)_4NH_2$, or $(CH_2)_3NHC(=O)NH_2$

R^5 is H; $CH(CH_3)(CH_3)$

R^6 is $NHC(=O)$, or CH_2;

n is 1 or 2; and

m is 0, 1, 2 or 3, and an antibody.

26. An antibody-drug conjugate of Claim 25 wherein the antibody is a monoclonal antibody.

27. An antibody-drug conjugate of Claim 25 wherein the antibody is specific to a cancer antigen.

28. An antibody-drug conjugate of Claim 25 wherein the antibody is alemtuzumab, bevacizumab, brentuximab, cetuximab, gemtuzumab, ipilimumab, ofatumumab, panitumumab, rituximab, tositumomab, or trastuzumab.

29. An antibody-drug conjugate which is a conjugate of a compound of the Formula (IIi)



(IIi) and an antibody.

30. An antibody-drug conjugate which is a conjugate of a compound of the Formula (IIii)



(IIii)

and an antibody.

31. An antibody-drug conjugate which is a conjugate of a compound of the Formula (IIiii)



(IIiii)

and an antibody.

32. An antibody-drug conjugate which is a conjugate of a compound of the Formula (IIiv)



(IIiv)

33. A pharmaceutical composition containing a compound of any one of Claims 1-24.

34. A pharmaceutical composition containing an antibody-drug conjugate of any one of Claims 25-32.

35. Use of a compound of any one of Claims 1-24 in the manufacture of a medicament for treating cancer.

36. Use of an antibody-drug conjugate of any one of Claims 25-32 in the manufacture of a medicament for treating cancer.

37. The use according to Claim 35 or 36 wherein the cancer is selected from squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, myeloma, salivary gland carcinoma, kidney cancer, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, head and neck cancers, mucinous ovarian cancer, cholangiocarcinoma or renal papillary carcinoma.